CAV1 and prostate carcinoma: The initial studies focussed on breast cancer, but more recently it became clear that the loss or the weak expression of CAV1 in the cancer stroma is correlated with adverse prognosis for a variety of cancers, such as gastric cancer, pancreatic adenocarcinoma, prostate cancer, and colorectal cancer7–12.